FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 79 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR EMA Adopts a Positive Opinion for Biosimilar Denosumab May 28, 2025 The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer... March 13, 2020 Delivering the future of paediatric brain tumour therapy October 7, 2021 Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL September 21, 2021 Load more HOT NEWS FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type...
